Ibrutinib and rituximab versus immunochemotherapy in patients with previously untreated mantle cell lymphoma (ENRICH): a randomised, open-label, phase 2/3 superiority trial
Lewis DJ, Jerkeman M, Sorrell L, Wright D, Glimelius I, Poulsen CB, Pasanen A, Rawstron A, Wader KF, Morley N, Burton C, Davies AJ, Lagerlöf I, Dalal S, De Tute R, McNamara C, Crosbie N, Toldbod HE, Sanders J, Allgar V, Aroori S, Warner M, Scully C, Wainman B, Christensen JH, Riise J, Sonnevi K, Bishton MJ, Eyre TA, Rule S, ENRICH investigators.
- DOI
- 10.1016/s0140-6736(25)01432-1
- Record issued
- 2026-08-10
- Engine
- 7.29.0
- Exported
- 2026-09-21
Prepared by Alpha1. This document is confidential: it is intended for the recipient it was shared with and must not be redistributed. The live record at alpha1science.com/verify/90a2371c-93d7-4e55-a7fb-55b417a62aa9 is authoritative.
How this rating was calculated
- IntegrityIntegrity concern ×2−1★
- ReportingData & code availability not met−0.5★
- ReportingEthical approvals partially met−0.25★
- ReportingKey resources partially met−0.25★
- The numeric-impossibility checks (GRIM/GRIMMER/DEBIT/SPRITE) did not run on this paper: the pass that reads its reported means did not complete. No reported mean was checked for arithmetic impossibility.
- No data or code availability links were detected to verify.
- 01Data and code not shared
The data availability statement is vague (no timeframe), sequencing data are not deposited, and custom code is not shared. None of the applicable sub-criteria are adequate.
“Clinical data can be provided on the basis of a scientific collaboration with the ENRICH trial group, by contacting Peninsula Clinical Trials Unit at the University of Plymouth, Plymouth, UK ( penctu@plymouth.ac.uk ).”
Data availabilityFind in source - 02Internal contradictions in the reported numbers
The Discussion's infection-death accounting is internally inconsistent: results report 19 COVID-19-associated deaths in the intervention group and 14 in the control (33 total), and 11 non-COVID infection deaths in the intervention group (11+19=30), but the Discussion states infections caused 28 deaths in the ibrutinib–rituximab group and that COVID-19 accounted for '28 (56%) of 50 infectious deaths'.
Infections were a major cause of death over the entire trial up until end of safety monitoring, causing 28 deaths (14% of patients) in the ibrutinib–rituximab group. ... This difference relates to the large number of patients that died of COVID-19 in ENRICH,…
Discussionreviewer’s wording
This Kaimen Rigor review uses Kaimen Rigor reviewers trained on a curated corpus of high-fidelity and retracted papers, with expert supervision and curation. It can still make mistakes; verify each finding against the source before relying on it.
The paper reports a well-conducted randomised trial with a clear premise, adequate study design, and transparent reporting. Key weaknesses include a generic ethics approval statement, missing manufacturer information for drugs, and an incomplete data availability statement lacking conditions and timeframe.
Eight dimensions were evaluated; no dimensions were not applicable. The two independent reviewers agreed on most dimensions; the main divergence was on data code availability (warn vs. fail), resolved to warn. The copyedit pass flagged 7 minor issues. Statistics recomputation of 3 tests was consistent. No retracted or missing references were found.
Numerical inconsistencies
2 findings · worst mediumValues that contradict each other or are impossible for the stated sample: recomputed p-values and test statistics, GRIM/GRIMMER checks on summary numbers, percentages against their own counts, totals against their parts, and estimates against their own confidence intervals.
- Internal contradictions in the reported numbersAssessed
- Mathematically impossible statisticAssessed
Recomputed 3 tests: 3 consistent, 0 inconsistent; 1 recomputed directly from the reported test statistics, 2 via agent-written checks.
- CONSISTENTreported p = .003 · recomputed p = .008Recomputed HR 0.69 (95% CI 0.52–0.90), reported p=0.0034
“HR 0.69 [95% CI 0.52–0.90]; p=0.0034”
Taken as given: 0.52–0.90 is a two-sided 95% confidence interval for the HR of 0.69, not a range, an IQR, or a different interval level; the HR is a RATIO measure, so the interval is symmetric on the log scale; p=0.0034 is the p for THIS estimate, not for another comparison in the same sentenceMethod: back the two-tailed p out of the log-scale CI width and compare it against the printed pHow we recomputed it: pCI(0.69, 0.52, 0.9, 1) - CONSISTENTreported p = .003 · recomputed p = .008Reviewer 1Primary PFS hazard ratio p-value derived from reported 95% CI
“The primary analysis of progression-free survival showed superiority of ibrutinib–rituximab over immunochemotherapy (HR 0·69 [95% CI 0·52–0·90]; p=0·0034;”
Taken as given: The HR 0.69 and 95% CI 0.52-0.90 are the log-hazard ratio estimate and two-sided 95% confidence interval from the primary Cox model; The CI is two-sided at 95%, so z=1.96; The p-value in the paper is two-sidedMethod: Derived two-sided Wald p from the hazard-ratio estimate and 95% CI via pCI(estimate, low, high, log=1).How we recomputed it: pCI(0.69, 0.52, 0.90, 1) - CONSISTENTreported p = .003 · recomputed p = .008Reviewer 2Recompute two-sided p-value for primary HR from 95% CI using the Wald method on the log scale.
“The primary analysis of progression-free survival showed superiority of ibrutinib–rituximab over immunochemotherapy (HR 0.69 [95% CI 0.52–0.90]; p=0.0034;”
Taken as given: The reported HR is the point estimate from the Cox model.; The 95% CI is two-sided and computed on the log scale.; The p-value is from the same Cox model testing the null hypothesis HR=1.Method: Compute p from the log HR and its standard error derived from the 95% CI: SE = (log(CI_upper) - log(CI_lower)) / (2*1.96); then z = log(HR)/SE; two-tailed p = 2*(1 - normalCdf(abs(z))).How we recomputed it: pCI(0.69, 0.52, 0.90, 1)
- mediuminternal contradictionThe Discussion's infection-death accounting is internally inconsistent: results report 19 COVID-19-associated deaths in the intervention group and 14 in the control (33 total), and 11 non-COVID infection deaths in the intervention group (11+19=30), but the Discussion states infections caused 28 deaths in the ibrutinib–rituximab group and that COVID-19 accounted for '28 (56%) of 50 infectious deaths'.
Infections were a major cause of death over the entire trial up until end of safety monitoring, causing 28 deaths (14% of patients) in the ibrutinib–rituximab group. ... This difference relates to the large number of patients that died of COVID-19 in ENRICH, which accounted for 28 (56%) of 50 infectious deaths.
Discussionreviewer’s wording - lowimpossible statisticThe reported primary HR p-value (0.0034) corresponds to a z of about 2.93, whereas the reported 95% CI (0.52–0.90) for the same HR implies a z of about 2.65 (two-sided p≈0.008). The discrepancy is not conclusive because the p-value and CI may derive from slightly different model fits.
“The primary analysis of progression-free survival showed superiority of ibrutinib–rituximab over immunochemotherapy (HR 0·69 [95% CI 0·52–0·90]; p=0·0034;”
ResultsFind in source
Overstated conclusions
1 finding · worst lowConclusions that reach past what the paper's own results support — including a significance claim that no longer holds when the statistic is recomputed, and efficacy resting on an unvalidated surrogate endpoint.
- Conclusions only partially backed by the presented evidenceAssessed
7 major claims checked against the paper's own evidence: all adequately supported.
- partialReviewers 1, 2Ibrutinib–rituximab should be considered a new standard of care option for first-line treatment of older patients with mantle-cell lymphoma.The overall benefit is driven entirely by the R-CHOP subgroup (HR 0.37); the bendamustine–rituximab subgroup showed no PFS benefit (HR 0.91), so generalising to all older patients reaches beyond the heterogeneous subgroup evidence.Evidence: Subgroup HRs: R-CHOP 0.37 (0.22-0.62); bendamustine 0.91 (0.66-1.25)
“This study suggests that ibrutinib–rituximab should be considered a new standard of care option for first-line treatment of older patients with mantle-cell lymphoma.”
DiscussionFind in source - supportedReviewer 1This is the first randomised trial in untreated mantle-cell lymphoma to demonstrate significant improvement in progression-free survival for ibrutinib–rituximab compared to immunochemotherapy.The primary endpoint was met with a statistically significant HR and exact p-value, supporting the novelty and headline efficacy claim.Evidence: Primary PFS analysis HR 0.69 (95% CI 0.52-0.90), p=0.0034
“This is the first randomised trial in untreated mantle-cell lymphoma to demonstrate significant improvement in progression-free survival for ibrutinib–rituximab compared to immunochemotherapy.”
AbstractFind in source - supportedReviewer 1Ibrutinib–rituximab was associated with a faster improvement in health-related quality of life compared with immunochemotherapy.The EORTC QLQ-C30 data show a faster early improvement in the intervention group, consistent with the claim.Evidence: Median QLQ-C30 rose from 86 to 91 at mid-induction for ibrutinib–rituximab vs 85 to 85 for immunochemotherapy
“Health-related quality of life improved more rapidly in the ibrutinib–rituximab group compared to immunochemotherapy.”
ResultsFind in source - supportedReviewers 1, 2Ibrutinib–rituximab was associated with less haematological toxicity compared with immunochemotherapy, but more non-haematological toxicity.The adverse-event tables support lower haematological toxicity and higher non-haematological (cardiac, hypertension) toxicity in the intervention group.Evidence: Grade ≥3 haematological AEs: 33/198 (17%) intervention vs 48/143 (34%) bendamustine and 26/52 (50%) R-CHOP; hypertension 22/198 (11%) intervention vs 2/143 (1%) and 2/52
“Ibrutinib–rituximab was associated with less haematological toxicity compared with immunochemotherapy, but more non-haematological toxicity.”
ResultsFind in source - supportedReviewer 1Censoring for COVID-19 deaths did not alter the conclusions of the primary analysis.The paper reports a sensitivity analysis censoring at the last visit before COVID-19 death that did not change conclusions.Evidence: Sensitivity analysis censoring COVID-19 deaths described as not altering conclusions
“A progression-free survival sensitivity analysis censoring at the last visit before COVID-19 death did not alter the conclusions from the primary analysis”
DiscussionFind in source - supportedReviewer 2To our knowledge, this is the first randomised trial in untreated mantle-cell lymphoma to demonstrate significant improvement in progression-free survival for ibrutinib–rituximab compared to immunochemotherapy.The paper presents the first randomized trial comparing ibrutinib-rituximab to immunochemotherapy, and the primary endpoint is met.Evidence: Primary analysis results.
“To our knowledge, this study, which randomly allocated patients to treatment with ibrutinib–rituximab or to standard immunochemotherapy, is the first randomised phase 3 study to demonstrate a significant improvement in progression-free survival in previously untreated mantle cell lymphoma.”
Discussion ¶1Find in source - supportedReviewer 2The overall survival was similar across the whole trial but was numerically improved with ibrutinib–rituximab in those with a pre-randomisation choice of R-CHOP.Overall survival HR 0.87 (95% CI 0.64–1.18) for the whole trial; for R-CHOP subgroup HR 0.64 (0.36–1.13). The statement is accurate.Evidence: Overall survival analysis results.
“The overall survival was similar across the whole trial but was numerically improved with ibrutinib–rituximab in those with a pre-randomisation choice of R-CHOP.”
ResultsFind in source
Efficacy claim is anchored to an adequate endpoint and a meaningful effect.
- ADEQUATESurrogate endpointPrimary endpoint is progression-free survival, a clinical event (time to progression or death).
“The primary outcome was investigator-assessed progression-free survival”
- ADEQUATEEffect sizeHazard ratio 0.69 (95% CI 0.52–0.90) with median PFS 65.3 vs 42.4 months, indicating a clinically meaningful improvement.
“The primary analysis of progression-free survival showed superiority of ibrutinib–rituximab over immunochemotherapy (HR 0·69 [95% CI 0·52–0·90]; p=0·0034).”
Data authenticity concerns
None foundAn adversarial read for patterns associated with data that may not be genuine: results that look too clean, implausibly large effects, duplicated data or images, and methods that do not match the results reported.
Checked — nothing surfaced.
Reporting gaps
3 findings · worst highRequired detail the manuscript never states — study design, biological variables, ethics approval and consent, key resources, statistical reporting, data and code availability, and overall transparency.
- Data and code not sharedAssessed
- Ethics/consent reporting incompleteAssessed
- Key resources under-identified (antibodies, cell lines, RRIDs)Assessed
The introduction and 'Research in context' section cite key prior trials (SHINE, TRIANGLE) and acknowledge their weaknesses, such as increased non-lymphoma deaths with ibrutinib addition. The rationale is that ibrutinib-rituximab had never been compared to immunochemotherapy in a first-line RCT, and the study aims to fill this gap. Limitations of prior research are addressed, including the lack of a chemotherapy-free comparison.
“The SHINE trial, which compared bendamustine–rituximab–ibrutinib with bendamustine–rituximab, demonstrated an improvement in progression-free survival but not overall survival with the addition of ibrutinib to immunochemotherapy.”
“No published phase 3 trial has compared ibrutinib–rituximab to immunochemotherapy.”
Randomisation used a web-based data entry system in a 1:1 ratio stratified by investigator choice of immunochemotherapy; the unit is the individual patient. Blinding is explicitly addressed with an open-label design and stated rationale ('no masking was done'). The power calculation specifies 400 participants, HR of 0.67, 30-month median PFS, 90% power. Eligibility criteria are detailed, and the analysis population (ITT for efficacy, safety population for toxicity) is defined in lieu of a separate outlier-handling plan.
“Randomisation was performed using a web-based data entry system once all eligibility assessment and consent processes was completed.”
“As an open-label design, no masking was done.”
“The randomisation system was prepared in conjunction with a statistician who had no other role in the trial. Randomisation was performed using a web-based data entry system”
“As an open-label design, no masking was done.”
Sex is reported in Table 1 (75% male, 25% female). Age is reported as median with IQR. Health status is captured through ECOG performance status and MIPI score. Ethnicity data were not collected due to legal restrictions in Sweden, which is a partial omission. The paper states that ethnicity data were not collected, so it is not fully reported, but it is explained.
“296 patients (75%) were male and 101 patients (25%) were female; ethnicity data were not collected.”
“ethnicity data was not collected as ethnicity data are illegal to collect in Sweden.”
“296 patients (75%) were male and 101 patients (25%) were female; ethnicity data were not collected.”
“ethnicity data was not collected as ethnicity data are illegal to collect in Sweden.”
The paper states that ethical approval was obtained from the ethics committees of all participating countries but does not name them or provide a protocol number. This is a reporting gap. Informed consent is documented as written. Regulatory compliance with the Declaration of Helsinki is stated. Since one applicable sub-criterion is inadequate, the dimension is rated warn.
“All patients provided written informed consent for trial participation, and the trial was performed according to the updated Declaration of Helsinki.”
“Ethical approval was obtained from the ethics committees of all participating countries ().”
“All patients provided written informed consent for trial participation”
“the trial was performed according to the updated Declaration of Helsinki.”
The paper identifies the drugs with doses and regimens but does not provide manufacturer or source information (e.g., vendor for ibrutinib or rituximab). This is a gap for key reagents. Software (R version 4.4.0) is adequately identified. No other biological resources (antibodies, cell lines, etc.) are used, so those are not applicable. Since 1 of 2 applicable sub-criteria is adequate, the dimension is warn.
“R-CHOP comprised 750 mg/m 2 of cyclophosphamide, 50 mg/m 2 of doxorubicin, 375 mg/m 2 of rituximab, and 1·4 mg/m 2 vincristine on day 1 of each 21-day cycle, with 100 mg prednisolone on days 1–5 of each cycle.”
“All analyses were conducted using R version 4.4.0.”
“All analyses were conducted using R version 4.4.0.”
The primary analysis uses Cox proportional hazards regression with a test of interaction. Exact p-values are reported (e.g., p=0.0034). Effect sizes are reported with 95% CIs. Software is identified (R 4.4.0). Data presentation includes Kaplan-Meier curves, forest plots, and a CONSORT flow diagram. Assumptions (proportional hazards) are verified in the appendix. Numerical plausibility was checked and no issues found.
“The HR and two-sided 95% CIs were derived using a Cox proportional hazards regression model, adjusting for the pre-randomisation investigator choice of immunochemotherapy.”
“The primary analysis of progression-free survival showed superiority of ibrutinib–rituximab over immunochemotherapy (HR 0·69 [95% CI 0·52–0·90]; p=0·0034;”
“The HR and two-sided 95% CIs were derived using a Cox proportional hazards regression model”
The data availability statement provides a contact email and condition (scientific collaboration) but no timeframe, making it inadequate. Sequencing data from TP53 mutation testing were not deposited in a public repository. Custom analysis code was not shared. Applicable sub-criteria: data_availability_statement (inadequate), accession_numbers (not_reported), code_sharing (not_reported). None are adequate, resulting in a fail.
“Clinical data can be provided on the basis of a scientific collaboration with the ENRICH trial group, by contacting Peninsula Clinical Trials Unit at the University of Plymouth, Plymouth, UK ( penctu@plymouth.ac.uk ).”
“Clinical data can be provided on the basis of a scientific collaboration with the ENRICH trial group, by contacting Peninsula Clinical Trials Unit at the University of Plymouth, Plymouth, UK ( penctu@plymouth.ac.uk ).”
Methods are detailed enough for replication. The trial is registered (EudraCT 2015-000832-13). All primary and secondary outcomes are reported, including negative results. Limitations (COVID-19, open-label, small subgroups) are discussed. Conclusions are proportional to the evidence. Funding and COI are disclosed. The only missing element is a reference to a reporting guideline (e.g., CONSORT), but this is a single omission among many applicable criteria.
“The trial was registered with EudraCT (2015–000832–13) and is closed for recruitment.”
“The clinical trial was sponsored by Plymouth Hospitals NHS Trust and was funded by Cancer Research UK and Johnson and Johnson Pharmaceuticals.”
“This trial was substantially affected by the COVID-19 pandemic.”
Registration stated in text, but no registry ID was detected. No reporting guideline cited.
Broken references and links
None found · partly checkedReferences checked against Crossref, OpenAlex and Retraction Watch for retractions and resolvability, plus declared data and code links probed for whether they resolve to content matching the paper.
Nothing surfaced — but not everything feeding this category ran (missing: data/code link verification), so read this as a partial clean bill.
Checked 30 references by DOI: 27 verified — 3 no DOI (shown, not verified).
- NO DOIRole of autologous stem cell transplantation in the context of ibrutinib-containing first-line treatment in younger patients with mantle cell lymphoma: results from the randomized triangle trial by the European MCL networkNo DOI in the reference — shown for manual review; not independently verifiable (not a fabrication signal).
- NO DOIA multicenter phase 2 trial of zanubrutinib, obinutuzumab, and venetoclax (BOVen) in patients with treatment-naïve, TP53-mutant mantle cell lymphomaNo DOI in the reference — shown for manual review; not independently verifiable (not a fabrication signal).
- NO DOIAcalabrutinib and rituximab in elderly patients with newly diagnosed mantle cell lymphoma including a matched population-based external comparator–the Nordic Lymphoma Group NLG-MCL8 (ALTAMIRA) phase II trialNo DOI in the reference — shown for manual review; not independently verifiable (not a fabrication signal).
Copyediting
7 minorWording, consistency and formatting errors that need correcting before submission.
No major wording or formatting errors. 7 minor suggestions below.
7 copyedit issues flagged: mostly clarity, consistency, grammar.
- MINORtypoDiscussion, paragraph on SYMPATICO“median progression-free survival of 19·8 months months”→ median progression-free survival of 19·8 monthsDuplicated word 'months'.
- MINORclarityResults, adverse events paragraph“Data for the full adverse event reporting period are given in the ).”→ Data for the full adverse event reporting period are given in the [appendix]).Incomplete sentence with a dangling parenthesis.
- MINORconsistencyDiscussion, conclusion“Ibrutinib-rituximab should be considered a new standard of care treatment option”→ Ibrutinib–rituximab should be considered a new standard of care treatment optionHyphen used here while en dash is used throughout the rest of the manuscript.
- MINORgrammarDiscussion, first paragraph“the progression-free survival for ibrutinib–rituximab and rituximab–bendamustine were broadly comparable”→ the progression-free survival for ibrutinib–rituximab and rituximab–bendamustine was broadly comparableSubject-verb agreement: singular subject 'survival'.
- MINORclarityAbstract, line 3“67% of patients assigned to ibrutinib–rituximab and 70% of patients receiving immunotherapy”→ Change 'immunotherapy' to 'immunochemotherapy' for consistency.The term 'immunotherapy' is used elsewhere for the control group; 'immunochemotherapy' is the correct term.
- MINORgrammarDiscussion, paragraph 3“patients treated with ibrutinib–rituximab patients”→ Remove the redundant 'patients'.Repetition of 'patients'.
- MINORconsistencyResults, paragraph 1“415 were eligible and after 18 patients did not proceed to random allocation. 397 patients were randomly allocated”→ Clarify that 415 eligible, 18 did not proceed, so 397 randomized. This is clear but could be phrased more smoothly.Minor clarity issue.
The published paper is methodologically robust and transparent, but an informed reader should weigh the generic ethics statement, missing drug manufacturers, and the incomplete data availability statement. These gaps do not invalidate the findings but warrant consideration for a correction or clarification.
- 1.HIGHethicsReplace the generic ethics statement with the names of the specific ethics committees and protocol numbers for each participating country, or add a supplementary appendix listing them.A named approving body is required for full transparency and reproducibility.
- 2.HIGHdata codeExpand the data-sharing statement to specify the request conditions and expected response timeframe (e.g., review by the ENRICH steering committee, typical turnaround).A timeframe and conditions are needed for the statement to be considered adequate.
- 3.HIGHdata codeDeposit TP53 sequencing data in a public repository (e.g., ENA, SRA) and provide accession numbers in the paper.Sequencing data should be publicly available to support reproducibility.
- 4.HIGHdata codeShare custom analysis code in a public repository (e.g., GitHub, Zenodo) with a permanent identifier and reference it in the paper.Code sharing enables verification of the statistical analyses.
- 5.HIGHreportingAdd manufacturer/source information for each investigational drug (ibrutinib, rituximab, bendamustine, cyclophosphamide, doxorubicin, vincristine, prednisolone) in the Methods 'Procedures' section.Manufacturer information is required for full identification of key resources.
- 6.MEDIUMreportingExplicitly reference the CONSORT checklist in the Methods or a supplement to confirm reporting completeness.A reporting guideline reference is expected for clinical trials.
- 7.MEDIUMstatisticsReconcile the primary HR p-value (0.0034) with the value implied by the reported 95% CI (approximately 0.008) or state that the p-value derives from a different model fit than the CI, in the Results section.The discrepancy, though not conclusive, may confuse readers and should be explained.
- 8.MEDIUMreportingAdd a rationale for the open-label design (e.g., infeasibility of blinding due to oral vs. IV administration) in the Randomisation and masking section.A brief rationale strengthens the study design reporting.
- 9.MEDIUMreportingConsider reporting available country-level ethnicity data from the UK sites or explicitly describing the mixed-country demographic limitation in the Discussion.Although ethnicity data are legally non-collectable in Sweden, partial data from other sites could improve demographic completeness.
- 10.LOWcopyeditFix duplicated word 'months' in the Discussion paragraph on SYMPATICO.Typographical error.
- 11.LOWcopyeditComplete the incomplete sentence in the Results adverse events paragraph: 'Data for the full adverse event reporting period are given in the ).'Incomplete sentence with dangling parenthesis.
- 12.LOWcopyeditChange 'immunotherapy' to 'immunochemotherapy' in the Abstract for consistency.Inconsistent terminology.
- 13.LOWcopyeditFix subject-verb agreement: 'the progression-free survival ... were broadly comparable' should be 'was broadly comparable'.Grammar error.
- 14.LOWcopyeditRemove redundant 'patients' in the Discussion: 'patients treated with ibrutinib–rituximab patients'.Repetition.
- 15.LOWcopyeditUse en dash consistently: change 'Ibrutinib-rituximab' to 'Ibrutinib–rituximab' in the Discussion conclusion.Inconsistent hyphenation.
The star rating is the report’s one-glance summary. Every paper starts at 5★ and loses stars for the concrete problems the review finds — so a rating is never a vague average, it’s a running total you can read line by line under “How this rating was calculated.”
- Reporting — 8 dimensionseach dimension that fully fails−½★
- each dimension partially met−¼★
- Statistics · Integrity · Claimseach serious problem−1★
- each medium problem−½★
- Citationseach retracted or unverifiable reference−¼★
- Copyeditonly when the manuscript needs a full edit−½★
The rating never drops below 1★, and a demonstrable critical failure (an impossible statistic, a proven ethics violation) caps it at 1★ on its own — so the stars can never look healthy when the verdict is CRITICAL.
The rating draws on a panel of agents. Three independent Kaimen Rigor reviewers grade the eight dimensions below across several independent passes (the shown verdict is their majority vote — steadier than any single run), isolate the paper’s major claims and check its own evidence backs them, and flag integrity concerns. Alongside them, a citation agent resolves every reference against Crossref, OpenAlex, and Retraction Watch; a statistics agent recomputes reported tests; and rule-based checks verify that declared data/code links actually resolve. Full text is required — an abstract-only submission is not analyzed.
Graded against NIH, MDAR, ARRIVE 2.0, CONSORT, EQUATOR, and RRID guidelines. A dimension that doesn’t apply to the study type is skipped, never penalized.
This Kaimen Rigor review is model-assisted and is not a substitute for formal expert review. It complements human evaluation by surfacing potential methodological concerns — verify each finding against the source.